Literature DB >> 16123489

Monotonicity of nerve tests in diabetes: subclinical nerve dysfunction precedes diagnosis of polyneuropathy.

Peter J Dyck1, Peter C O'Brien, William J Litchy, C Michel Harper, Christopher J Klein, P James B Dyck.   

Abstract

OBJECTIVE: The objective of this study was to test whether monotone worsening of nerve function, attributable to diabetes, can be demonstrated before criteria for diabetic sensorimotor polyneuropathy (DSPN) have been met. Which nerve tests are best? RESEARCH DESIGN AND METHODS: From a prevalence cohort of 504 individuals in the Rochester Diabetic Neuropathy study (RDNS), we identified 238 individuals (group 1) who at first examination were without polyneuropathy (DSPN) by a sum score of the normal deviates (from percentiles) of five attributes of nerve conduction of the legs (i.e., their five nerve conduction normal deviate values were <97.5th percentile) and were followed longitudinally two or more times. Of these 238, 90 (group 2) were followed six or more times at yearly or bi-yearly intervals. We compared different nerve tests for the ones most sensitive and reliable in showing latent nerve dysfunction and monotone (the extent to which a variable measured repeatedly over time reveals a significant trend of worsening or improvement).
RESULTS: In group 1 patients, the mean sum score of five attributes of nerve conduction (sigma 5 NC nds) at baseline was 1.08 and at the last examination (only patients with Sigma 5 NC nds <97.5th percentile) was 3.63, markedly higher than that in healthy subjects (only of individuals with Sigma 5 NC nds <97.5th percentile) (-0.12), indicating a subtle latent shift of nerve conduction tests toward abnormality. Serial evaluations of many individual and especially sum scores of nerve conduction tests in group 2 patients showed statistically significant worsening with time, even when nerve conduction tests were still well within normal limits. Neurologic signs also worsened but barely to significant levels; however, symptoms and quantitative sensation tests did not. Considering the composite score sigma 5 NC nds, 42 (of 90 group 2 patients) showed significant worsening, 22 were still without DSPN by nerve conduction test criteria, and some were even below the 50th percentile at the last evaluation.
CONCLUSIONS: Subtle and latent functional worsening of nerve conduction can be demonstrated even before nerve conduction test criteria for DSPN have been met. For demonstrating monotone worsening, the order (from best to worst) of tests was: some composite scores of nerve conduction and individual attributes of nerve conduction. We did not show monotone worsening of symptoms or of quantitative sensation test results. In multivariate analysis of risk factors and their association with worsening sigma 5 NC nds, 24-h microalbuminuria (a marker of microvessel disease) was found to be a significant covariate, an indication that the asymptomatic alterations of nerve conduction are meaningful.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16123489     DOI: 10.2337/diacare.28.9.2192

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  24 in total

1.  Polyneuropathy dysfunction scores.

Authors:  P J Dyck; P C O'Brien
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-05-18       Impact factor: 10.154

2.  High Dietary Fat Consumption Impairs Axonal Mitochondrial Function In Vivo.

Authors:  Marija Sajic; Amy E Rumora; Anish A Kanhai; Giacomo Dentoni; Sharlini Varatharajah; Caroline Casey; Ryan D R Brown; Fabian Peters; Lucy M Hinder; Masha G Savelieff; Eva L Feldman; Kenneth J Smith
Journal:  J Neurosci       Date:  2021-03-30       Impact factor: 6.167

3.  Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Marcia Waddington Cruz; Violaine Planté-Bordeneuve; Pierre Lozeron; Ole B Suhr; Josep M Campistol; Isabel Maria Conceição; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Amy Wilson; Donna R Grogan
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

4.  Repeatability of nerve conduction measurements using automation.

Authors:  Xuan Kong; Eugene A Lesser; J Thomas Megerian; Shai N Gozani
Journal:  J Clin Monit Comput       Date:  2006-09-14       Impact factor: 2.502

5.  Low peripheral nerve conduction velocities and amplitudes are strongly related to diabetic microvascular complications in type 1 diabetes: the EURODIAB Prospective Complications Study.

Authors:  Morten Charles; Sabita S Soedamah-Muthu; Solomon Tesfaye; John H Fuller; Joseph C Arezzo; Nishi Chaturvedi; Daniel R Witte
Journal:  Diabetes Care       Date:  2010-09-07       Impact factor: 19.112

6.  Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.

Authors:  Dong Hwee Kim; Steven R Zeldenrust; Phillip A Low; Peter J Dyck
Journal:  Muscle Nerve       Date:  2009-09       Impact factor: 3.217

7.  Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.

Authors:  Giampaolo Merlini; Violaine Planté-Bordeneuve; Daniel P Judge; Hartmut Schmidt; Laura Obici; Stefano Perlini; Jeff Packman; Tara Tripp; Donna R Grogan
Journal:  J Cardiovasc Transl Res       Date:  2013-10-08       Impact factor: 4.132

Review 8.  The spectrum of diabetic neuropathies.

Authors:  Jennifer A Tracy; P James B Dyck
Journal:  Phys Med Rehabil Clin N Am       Date:  2008-02       Impact factor: 1.784

9.  Relationship between clinical features and gastric emptying disturbances in diabetes mellitus.

Authors:  Adil E Bharucha; Michael Camilleri; Lee A Forstrom; Alan R Zinsmeister
Journal:  Clin Endocrinol (Oxf)       Date:  2008-08-22       Impact factor: 3.478

10.  Repeatability of nerve conduction measurements derived entirely by computer methods.

Authors:  Xuan Kong; Eugene A Lesser; Shai N Gozani
Journal:  Biomed Eng Online       Date:  2009-11-06       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.